APLN and chronic kidney disease: Key strengths of our study include the large study population, inclusion of patients with CKD without confounding comorbidity, a well‐matched group of healthy volunteers, and use of an assay that reliably measures plasma apelin isoforms, the most abundant of which is [Pyr1]apelin‐13.41